The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 21; no. 12; pp. 2447 - 2448
Main Authors Simkens, L.H.J., Tol, J., Terstappen, L.W.M.M., Teerenstra, S., Punt, C.J.A., Nagtegaal, I.D.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2010
Oxford University Press
Subjects
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Biomarkers, Tumor - blood
Carcinoma - blood
Carcinoma - diagnosis
Carcinoma - drug therapy
Clinical Trials, Phase III as Topic
Colorectal Neoplasms - blood
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - drug therapy
Diagnostic Techniques and Procedures
Disease Progression
Endothelial Cells - pathology
Humans
Neoadjuvant Therapy
Neoplastic Cells, Circulating - pathology
Predictive Value of Tests
Prognosis
Randomized Controlled Trials as Topic
Online AccessGet full text

Cover

More Information
Bibliography:istex:4E078D71E65D87974F6C0C4EE43680D741BC439A
ark:/67375/HXZ-BKWR1B0F-S
SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-3
ObjectType-Undefined-2
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdq640